- Home
- / Mersana Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Mersana Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.9
2024-10-29
Market Capitalization
$250.3 M
2024-10-28
Revenue
$40.5 M
FY, 2024
CreditSafe Score
?
Score changed on Jul 18, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.4M | 25.2M | 17.5M | 10.6M | 42.1M | 828.0K | 43.0K | 26.6M | 36.9M | 40.5M |
| Revenue growth, % | 143.0% | |||||||||
| General and administrative expense | 5.3M | 7.0M | 10.5M | 16.3M | 17.3M | 21.9M | 36.9M | 57.0M | 59.5M | 40.8M |
| Operating expense total | 26.7M | 39.0M | 57.2M | 76.2M | 72.3M | 88.9M | 168.9M | 230.3M | 207.8M | 113.8M |
| Interest income | 2.0K | 121.0K | 2.2M | 424.0K | 65.0K | 2.9M | 12.1M | 8.4M | ||
| Interest expense | 910.0K | 1.4M | 234.0K | 359.0K | 1.3M | 3.3M | 4.1M | 3.5M | ||
| Pre tax profit | (68.8M) | |||||||||
| Income tax expense | 418.0K | |||||||||
| Net Income | (16.4M) | (13.7M) | (38.7M) | (64.3M) | (28.2M) | (88.0M) | (170.1M) | (204.2M) | (171.7M) | (69.2M) |
| EPS | (2.4) | (2.2) | (1.5) | (0.6) |